ARTICLE | Clinical News
Subcutaneous semaglutide: Phase IIIa data
December 14, 2015 8:00 AM UTC
The open-label, international Phase IIIa SUSTAIN 4 trial in 1,089 Type II diabetics previously treated with metformin with or without a sulfonylurea showed that once-weekly 0.5 and 1 mg subcutaneous s...